Episode Details
Back to EpisodesClinical update with Dr. Daniel Griffin
Description
In his weekly clinical update, Dr. Griffin with Vincent Racaniello discusses Vijay Prasad’s return to the FDA, revoking of COVID vaccine authorization for young children, the Legionnaires’ outbreak in Harlem, the new labeling requirements for Ixchiq, the infectious attenuated Chikungunya vaccine and the importation of H5 influenza virus in Antarctica, before Dr. Griffin deep dives into recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, guidelines for treating COVID-19, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines, where to find PEMGARDA, long COVID treatment center, where to go for answers to your long COVID questions, the association of “virus rebound” and post-acute sequelae among hospitalized patients, how virus infection particularly influenza and SARS-CoV-2 may ‘re-activate’ dormant cancer cells and contacting your federal government representative to stop the assault on science and biomedical research.
Subscribe (free): Apple Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episode- Prasad returns to the FDA (Washington Post)
- Pfizer Covid vaccine for young children may not be renewed by FDA (The Guardian)
- Report suggests FDA may not reauthorize Pfizer COVID vaccine for young kids (CIDRAP)
- Factors Associated With Pediatric COVID-19 Mortality: A Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Study (Journal of Pediatric Infectious Diseases Society)
- Legionnaires’ Disease: In Harlem (NYC Health)
- Recommended Pause in Use of Ixchiq (Chikungunya Vaccine, Live) in Individuals 60 Years of Age and Older While Postmarketing Safety Reports are Investigated (FDA)
- FDA Removes Recommended Pause in Use and Approves Required Updated Labeling (FDA)
- Chikungunya Vaccines (CDC: Chikungunya virus)
- Chikungunya in China (CDC: Travelers’ Health)
- Travelers’ health notices (CDC: Travelers’ Health)
- Areas at Risk for Chikungunya (CDC: Chikungunya virus)
- Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of a